In their British Ophthalmic Surveillance Unit (BOSU) study on dysthyroid optic neuropathy (DON), Wong and colleagues [1] report an annual incidence of 0.75 per million per annum, i.e. around 50 patients per year in the UK, which fits with previously published data [2]. Surprisingly however, almost half of their patients who were followed up for 9 months went on to have orbital decompression surgery (47%), despite initial medical therapy-and with a mean delay of only 2.5 months post presentation [1].
aim for a ciclosporin trough level of 150-200 micrograms/L during the first six months, then 100 to 150 mcg/L for the second six months and 50-100 mcg/L thereafter. Ciclosporin is then gradually withdrawn over six months after prednisolone the has been stopped.
Seventy of the 75 DON patients (93%) recovered their premorbid visual acuities and 69 of 75 patients (92%) recovered premorbid visual fields. Interestingly, only five patients required surgical decompression of their orbits following our medical regime, with all five having presented with complicated or delayed presentations.
These data point to a potential role for ciclosporin in helping to reduce the need for orbital decompression surgery in DON. Previously, we have shown that ciclosporin therapy rapidly reduces the circulating anti-TSH receptor antibody, further evidence of its utility for TED [4] . Orbital wall decompression is associated with significant risks: the BOSU study reports one patient who developed perception of light vision following surgery and another developed intractable diplopia. Encephalocraniocutaneous lipomatosis (ECCL) is a rare neurocutaneous syndrome. The unique clinical manifestations of the disease include ocular edema or hamartoma, abnormal skin on the head and neck, and corresponding hair loss on the scalp. Historical literature on ECCL consists mainly of case reports and does not present the common features of the disease. We present the characteristic manifestations of the eye and skin to provide ophthalmologists with a fuller understanding of in ECCL.
Clinical information
Four patients, all male, aged 3-18 years, presented with ophthalmologic disorders caused by local or diffuse hyperplasia of the ocular surface and had irregular granule-like lesions on the head or neck and unilateral visible granular raised lesions on the tongue mucosal surface (Fig. 1) . No brain abnormality was apparent on skull computed tomography, and focal calcification was visible on the wall of the eye. All patients had normal intelligence and no history of seizures. ocular surface tumor was removed with conjunctival sac reconstruction or lamellar keratoplasty. Pathological results: Two cases were corneal Sebaceous tumor (mature squamous tumor) and two cases were fibrous epithelial polyps. Discussion ECCL is a rare neurocutaneous syndrome with unknown etiology and multiple sporadic differences in ethnicity, gender, and family history. Since Haberland [1] described this syndrome in 1970, more than 60 instances of related disorders have been published worldwide, mainly reported via pediatrics, and neurosurgery cases [2, 3] . The main features of the syndrome include asymmetric skin damage to the head and neck, central nervous system abnormalities(CNS), ocular abnormalities, often bilaterally. hair loss in the local skin lesion area. The most common eye lesions in ECCL are ocular tumors around the eyeball and small skin nodules. Other rare eye abnormalities of the syndrome such as bilateral optic disk defects and lack of bilateral iris eyelid retraction have been reported [4] .
The occurrence of ECCL may be related to genetic variation, and it is speculated that autosomal gene mutations lead to ectodermal dysplasia, while chimerism may be the cause of mesenchymal tumors and angiogenesis. Syndromes that need to be differentiated from linear nevus sebaceous syndrome (LNS), and oculocerebrocutaneous syndrome (OCC). A diagnosis of OCC needs to include CNS cysts or hydrocephalus, small eyeballs with orbital cysts. Skin lesions of LNS are mainly located in the midline of the face forming a linear pattern. According to the revised ECCL diagnostic criteria (Table 1) by Moog [5] in 2009, The ECCL diagnosis of these four cases is clear.
This group of patients shared the following common clinical features of ECCL: (1) ocular lesions; (2) flaky granular pigmentation of the area of skin loss; (3) granular mucosa visible on the surface of the tongue not observed in the previous literature. Ophthalmologists should consider the diagnosis of ECCL in their assessment if they encounter patients with these common characteristics.
There is no specific treatment for ECCL. The main ophthalmic approach is surgical removal of local bud tumors, with improvement of the cosmetic appearance as far as possible. We read with interest Meel and Dhiman's recent proposal for a new classification for ocular surface squamous neoplasia (OSSN) [1] . The authors offer a modified criteria for conjunctival neoplasia that takes into account invasion (on ultrasound biomicrosopy (UBM)) and provides a rough guide for treatment. They suggest that OSSN of Grade III (with intraocular involvement present) should be managed with enucleation.
The potential of advanced ocular surface squamous lesions to invade through the sclera or cornea is well recognised with enucleation being the traditional management [2] . However, many studies over the past decade have shown success with globe-sparing therapy for these advanced lesions-and it is certainly our experience that invasive squamous lesions can be managed in this way [3] . Shields et al. showed that plaque brachytherapy is a safe and reliable alternative to globe removal for eyes with conjunctival squamous cell carcinoma (SCC) showing scleral invasion and/or intraocular involvement [2] . Further, Graue et al. demonstrated local tumour control in 75% of recalcitrant conjunctival SCCs treated with electron beam radiotherapy [4] .
The relevance of the American Joint Committee on Cancer (AJCC) staging of conjunctival SCC in guiding initial management was challenged in a recent work by Belleverie et al. [5] . They also suggest reclassification of the T3 category (diffuse vs deep invading) to better guide initial treatment. However, similar to previous reports, these authors also advocate the use of surface brachytherapy for scleral invasion of SCC [5] .
The AJCC publications are recognised as authoritative guides for cancer staging and communicating information about cancer. Evidence-based staging is important to guide therapy and define prognosis, and the AJCC aims to help doctors design a treatment plan for individual patients. Meel and Dhiman's proposal include treatment in their modified staging system, and, although these management options are perhaps not available in their centre, we feel it would be useful to include staged options of therapy for advanced lesions as alternative to enucleation [1] . There appears to be an error in the classification table, listing Grade II lesions incorrectly as having no invasion into ocular coats on imaging, which contradicts the imaging findings and manuscript definitions of this grade.
We support the current classification system published by the AJCC, but agree with recent studies suggesting reclassification of the T3 category [5] . We thank McGrath and Salvi [1] for their valuable comments and suggestions. There are no published guidelines for treatment of ocular surface squamous neoplasia (OSSN). Also, clinical spectrum of OSSN varies significantly between different continents like Africa and North America or Australia [2] . Clinical presentation is significantly delayed in resource-constrained countries, and hence use of conservative management options like plaque brachytherapy are not only limited by availability but also by feasibility.
The conventional method of treatment for OSSN is wide local surgical excision using a 'no touch technique' and cryotherapy of conjunctival edges. Topical treatment with chemotherapeutic agents and interferons has become popular in the past 1-2 decades due to the inherent benefits of topical treatment-treatment of a complete ocular surface, thus reducing the chances of microscopic residual disease, lesser side effects of treatment as compared to surgical excision, especially in giant or diffuse tumors and the relative ease of administering treatment. Traditionally, enucleation is done for tumors with intraocular extension and exenteration for OSSN with orbital extension.
We agree with the authors that, technology-dependent treatment modalities, like plaque brachytherapy and proton beam therapy may not be available in resource-constrained countries. There are adequate reports in literature to show that brachytherapy effectively controls OSSN invading into the ocular coats and hence may be used as an adjuvant treatment in cases with incomplete tumor resection (Table 1 ) (the same has been added in the treatment options for grade II tumor in the revised table) [3] . However, its use in OSSN with overt (obvious on imaging (UBM) or clinically) intraocular extension is still being explored and needs to be evaluated in further studies [4] . We, at our center are now using adjuvant plaque brachytherapy in cases of invasive SCC, where there is microscopic residual disease in the ocular coats after surgery.
The proposed classification attempts to address the concerns with AJCC classification, as reported by previous studies and intends to give a rough guideline for treatment based on most commonly available treatment modalities [4] . While enucleation and exenteration remain the most common method of treatment for tumor with ocular and orbital extension, respectively, the treatment scenario for OSSN with ) . Till the time, further studies evaluate and define the role of other possible treatment options for intraocular and orbital disease like external beam radiotherapy, brachytherapy, or intraorbital interferon injections for a possible staged management approach; this classification may help guide treatment with the more established treatment options [5, 6] .
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Conflict of interest The authors declare that they have no conflict of interest. Patients suspected of having neovascular age-related macular degeneration (nAMD) requires rapid access to specialist clinics for confirmatory diagnosis and subsequent treatment. The Royal College of Ophthalmologists (RCOphth) guidelines [1] recommend <7 days delay between initial referral in primary care to assessment with a specialist in macular disease, and for those patients requiring treatment <7 days delay between specialist consultation and initial treatment. In order to achieve this the Oxford Eye Hospital utilises the 'Wet AMD rapid access referral form' developed by the Thames Valley Macular Group, adopted by the RCOphth and endorsed by the Macular Society and RNIB for all referrals to the dedicated rapid-access clinic for patients with suspected nAMD [2] . To address the concern that rapid-access referrals were being missed and booked into routine clinics, a streamlined e-mail referral system was created using a dedicated nhs.net email account from August 2014. Despite this system being widely shared with primary care providers. many referrals to our service are via other routes. We have audited the delay in access to specialist clinic for each referral route for 98 new AMD referrals seen in clinic between January and March 2018. Only 33.7% of referrals were received thorough the dedicated e-mail address, with 19.4% via the walk-in eye casualty service or other sub-specialist clinics and the remaining 46.9% via the patients' general preactitioners (GPs). Figure 1 shows the delay between referral and first specialist review for patients in each of the three referral groups. No patients referred via their (GP) were seen within the 7 days target. The differences in the proportions of patients seen between the e-mail referral group and GP referral group within 2 weeks (p = 0.0014) and within 3 weeks (p < 0.0001) were statistically significant (chi-squared test).
Overall 28.6% of patients referred were found to have nAMD in at least one eye. Figure 2 shows the delay between referral and specialist review for those patients found to have nAMD and those with other diagnoses. It shows that many patients who are subsequently confirmed to have nAMD are facing delays in accessing specialist review.
This work shows that, while there are other challenges in seeing patients in a timely manner, the use of a dedicated email referral system for nAMD can significantly reduce delays in patients being seen in specialist macular clinics compared to traditional GP-centred referral systems, and the importance of reinforcing the use of this system by optometrists and other providers of primary ophthalmic services in the community. It also highlights the need for more training of community optometrists to ensure that the rapid access pathway is used only for nAMD. The World Health Organization-endorsed rapid assessment of avoidable blindness (RAAB) survey employs pinhole acuity to distinguish between refractive error versus conditions not correctable with eyeglasses, but few studies have validated this approach [1] .
Methods
Ethical committees at the University of California, San Francisco and Narayana Nethralya Eye Hospital approved this study. A consecutive series of patients aged ≥50 years visiting the refraction clinic at Narayana Nethralaya Eye Hospital (Bangalore, India) in September 2015 had presenting vision and pinhole vision assessed using an ETDRS chart in a fully illuminated room, and then had a manifest refraction by an experienced optometrist. Analyses are reported with bootstrapped 95% confidence intervals with resampling at the participant level to account for nonindependence of eyes. Fig. 1 ). On average, pinhole acuity was less than a letter different from BCVA (mean 0.4 letters better, 95% limits of agreement by Bland-Altman method: four letters worse to five letters better). The magnitude of improvement on pinhole testing was correlated with the magnitude of spherical equivalent from refraction (Spearman's rho = 0.68, P < 0.001; Fig. 2 ). Of 204 eyes, 21 (10.3%) had visual impairment even after subjective refraction (BCVA worse than 20/60). When treated as a diagnostic test for visual impairment not correctable with eyeglasses, pinhole acuity provided high discriminative ability, with an area under the receiver operating characteristics (ROC) curve of 0.99 (95% CI: 0.97-1.0). Pinhole acuity worse than 20/60 was 85.7% sensitive (95% CI: 59.1-100%) and 100% specific (98.0-100%) for detecting visual impairment not correctable with glasses, and had a positive predictive value of 100% (95% CI: 81.4-100%).
Conclusions
Previous studies of patients with diabetic retinopathy or low vision found that pinhole acuity was biased relative to BCVA, with pinhole acuity~1 line worse than BCVA [2, 3] . In contrast, we found essentially no bias in this population from a refraction clinic in India. The reason for the discrepancy is unclear, but the pinhole occluder may cause more visual degradation in those with retinal pathology than in a general population like ours [2] . The estimates of sensitivity and specificity of pinhole acuity as a test for visual impairment are consistent with prior reports, and suggest that estimates of refractive error based on pinhole occlusion should not overestimate the prevalence of disease [4] .
In summary, pinhole acuity agreed well with BCVA and was a specific test for visual impairment not correctable with eyeglasses. These results suggest that pinhole occlusion is a valid gauge of refractive error in the RAAB survey or other community-based surveys. 
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of interest. Fig. 2 Relationship between improvement with pinhole occlusion and refractive error. Eyes were stratified according to how many lines of improvement were achieved with pinhole occlusion. The distribution of spherical equivalent for each stratum is depicted as a box-andwhiskers plot Fig. 1 Correlation between measurements of best spectacle corrected visual acuity and pinhole acuity. Points are weighted; the area of the circles represents the number of observations at each coordinate Cycloplegic retinoscopy is the gold standard refraction approach in children. Various protocols are in use to achieve cycloplegia during outpatient appointments. Many use not only the muscarinergic antagonist, cyclopentolate (CP), which paralyses the ciliary muscle, but also the alphaadrenergic agonist, phenylephrine (PE), which as a mydriatic paralyses the iris constrictor, but has no effect on the ciliary muscle. Whilst mydriasis facilitates visualisation of the retinoscopy reflex, there is a risk of underestimating hypermetropia. Published evidence suggests that repeated instillation of CP only is effective even for brown and very dark irides [1] [2] [3] .
To develop a Patient Group Directive (PGD) we carried out a two-cycle audit (CA18/PA/02). The first round evaluated our current protocol: blue iris, CP 1% once (0.5% if age < 3 months); brown iris, CP/PE 2.5% once; very dark iris, CP/PE twice, 10-15 min apart; repeated if pupils still constrict on pentorch illumination. As standard, we set full dilation in 90% within 30 min, i.e. the level expected for blue irides with a single CP drop [4] .
In the second round, we only included children with brown or very dark iris, administering CP twice or three times, respectively, 10-15 min apart. We assessed pupil constriction to pentorch illumination, standard when deciding whether additional drops are required. We also noted time from instillation of the first drop to pentorch test.
We evaluated 107 consecutive children (Table 1 ). Round 1 found that pupils were dilated in 97% of children with blue, 73% with brown, and 23% with very dark iris (Fig. 1) , at a mean 24 min (SD 18) after first drop. Repeat instillation increased success to 100%, 91%, and 85%, respectively. In the second round, pupil dilation was achieved in all children with brown iris, and in 89% with very dark iris, at a mean 32 min (SD 13) after first instillation.
Our use of pupil constriction as outcome measure, which assesses mydriasis, not cycloplegia, is a limitation. However, as we found that better dilation is achieved without the use of PE, this audit has changed our practice and contributed positively to the development of the PGD. Previous studies have identified the potential role of temperature and barometric pressure in contributing to a flare of inflammatory symptoms in susceptible rheumotological patients, but this association is controversial and not definitive [1, 2] . Joint inflammation is due in part to the proinflammatory role of matrix metalloproteinases (MMPs); enzymes which also have a destructive role towards the corneal extracellular matrix [3] . We wanted to perform a 10-year review of corneal perforations requiring cyanoacrylate gluing in theatre at our university tertiary referral centre to assess for any seasonal association [4] . Patients who underwent emergency gluing procedures in theatre for corneal perforation at Gartnavel General Hospital, Glasgow between 2008 and 2017 were identified from theatre logbooks and their electronic records retrospectively analysed. Audit data included patient demographics, date of perforation, ocular co-morbidities and any associated systemic conditions. There were 65 episodes in 43 patients of corneal perforation requiring gluing in this 10-year period. All identified cases were treated with application of cyanoacrylate glue. The majority of perforations (27/43; 63%) occurred in patients >60 years of age, and of female gender (25/43; 58%). Of the 43 patients, ten had an underlying systemic connective tissue disorder such as rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE), nine had infectious keratitis, six had an inflammatory ocular surface (rosacea, ocular cicatrical pemphigoid, blepharitis), five were graft failures, three had corneal ectasias, seven fell into the 'other causes' category (including trauma, exposure, post-LASIK), and no clear cause was documented in three patients. There were five patients who had three or more episodes of perforation; underlying diagnoses in these patients included Logic syndrome, SLE and rosacea keratitis.
There was a slightly higher incidence of corneal perforations in the spring and summer months (17 episodes in spring, 22 summer, 13 autumn, 13 winter). This association did not reach statistical significance (Chi-square p = 0.485). With respect to those patients with underlying systemic connective tissue disorders, eight episodes occurred in the spring/summer months and eight in autumn/winter (see Figs. 1 and 2) .
Average temperatures in Scotland range from 3 to 15 degrees Celsius (°C), with mean and median temperatures of 9°C. [See 'Scotland's Environment' from the Scottish Government, accessible at https://www. environment.gov.scot/media/1185/climate-climate.pdf]. We did not identify an increase in corneal perforations according to traditionally colder seasons in Scotland; rather, there was a slightly higher incidence in the spring/ summer. This was not statistically significant, possibly due to the small sample size and the lack of extreme temperatures between the Scottish seasons. We could not identify any reports linking weather conditions and corneal melting in the ophthalmic literature. Diseasemodifying anti-rheumatic drugs have previously been shown to improve the visual outcome in rheumatological patients with corneal melting, but this only implicates the presence of cellular inflammation, not the contributing factors for a flare in the underlying inflammatory condition [5] . A larger prospective study analysing these factors would be required to explore any link between seasonal variation and corneal melting leading to perforation. Fig. 2 Clinical photographs illustrating use of cyanoacrylate glue in the management of corneal perforations, either as direct application or in association with a plastic disc (punched from the plastic drape by a skin biopsy trephine) Fig. 1 Amvisc syringe assembly as provided out of packaging (a). The grey 'tip cap' (blue arrow) has to be screwed off the 'luer-lock' (red arrow) and then cannula (with luer) tightened within the luer-lock for correct assembly (b). It is possible to detach the luer-lock from the end of the Amvisc syringe, obviously going against the manufacturers instructions (c). However, this makes it possible for a surgeon to be handed an inappropriately assembled OVD that poses a danger of forceful detachment (d). An Alcon Viscoat syringe assembly (e). The syringe tip has a non-detachable moulded luer-lock (red arrow) that cannot be removed. To act as a safeguard from failure to correctly tighten the lure-lock by rotating the cannula to the full length of the sleeve threads, the design is improved by the inclusion of a yellow cannula locking cap (f). By applying the locking cap against the cannula hub, the cannula cannot act as a projectile
